Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 10/20 | 0.47 |
| ▸ | CA12 | O43570 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RPA1 | P27694 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.43 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19624841 | 0.88 | ALPL (0.60) | ALPLCA12KDM4ECA9RPA1 | |
| SCHEMBL19544616 | 0.83 | ALPL (0.65) | ALPLCA12MAPTCA9RAB9A | |
| SCHEMBL13539275 | 0.76 | ALPL (0.76) | ALPLCA12MAPTCA9RAB9A | |
| SCHEMBL13539269 | 0.76 | ALPL (0.73) | ALPLCA12MAPTCA9RAB9A | |
| SCHEMBL13539270 | 0.75 | ALPL (0.73) | ALPLCA12MAPTCA9RAB9A | |
| SCHEMBL13539283 | 0.75 | ALPL (0.73) | ALPLCA12MAPTCA9RAB9A | |
| SCHEMBL10242682 | 0.75 | TP53 (0.74) | ALPLCA12KDM4EMAPTPOLB | |
| SCHEMBL13539277 | 0.74 | KDM4E (0.78) | ALPLKDM4EMAPTCA9RAB9A | |
| SCHEMBL22414089 | 0.73 | HDAC3 (0.53) | ALPLCA12MAPTCA9RAB9A | |
| SCHEMBL19533574 | 0.73 | ALPL (0.53) | ALPLCA12MAPTCA9RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170313683-A1 | BTK INHIBITOR | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) | 2017-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313683-A1 | BTK INHIBITOR | BTK, SYK, LYN | ALPL 3689/4885CA12 4547/4885KDM4E 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.